- ►alfediam.org [PDF] B Verges - Diabetes and Metabolism, 2004 - Elsevier Cardiovascular disease is significantly increased in patients with metabolic syndrome and type
2 diabetes. Several factors such as chronic hyperglycemia, lipid abnormalities, endothelium
dysfunction, inflammation, oxidative stress, increased thrombosis and decreased ... Cited by 57 - Related articles - BL Direct - All 4 versions
MO Goodarzi, M Bryer-Ash - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 28 - Related articles - BL Direct - All 4 versions
- ►endojournals.org A Gastaldelli, Y Miyazaki, M Pettiti, E Santini, D … - Journal of Clinical …, 2006 - Endocrine Soc Results: Compared with placebo, RSG reduced fasting plasma glucose (9.7 ± 0.7 to 7.4 ± 0.3
mmol/liter; P < 0.001), fasting fractional GNG (–15 ± 4%; P = 0.002), and fasting GNG flux (–3.9
± 1.2 µmol/min/kg fat-free mass; P = 0.004), with no effect on glycogenolytic flux. Changes ... Cited by 23 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org A Gastaldelli, Y Miyazaki, A Mahankali, R Berria, M … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Fasting plasma glucose (FPG) (10.0 ± 0.8 to 7.7 ± 0.7 mmol/l) and HbA 1c (9.0 ±
0.4 to 7.3 ± 0.6%) decreased in the PIO and increased in Plc group (P < 0.05 PIO vs. Plc). Insulin
sensitivity increased ∼40% during high insulin clamp after pioglitazone (P < 0.01) and ... Cited by 24 - Related articles - BL Direct - All 5 versions
J Seufert, G Lübben, K Dietrich, PC Bates - Clinical therapeutics, 2004 - Elsevier Background: Type 2 diabetes mellitus is a condition characterized by impaired insulin secretion
and resistance to insulin-mediated glucose uptake and utilization. A number of oral antidiabetic
medication are available for its treatment, including metformin and the thiazolidinediones ( ... Cited by 16 - Related articles - All 4 versions
A Eriksson, S Attvall, M Bonnier, JW Eriksson … - Diabetes Obes …, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 12 - Related articles - All 6 versions
P Iozzo, R Lautamaki, F Geisler, KA Virtanen, V … - Diabetologia, 2004 - Springer Aims/hypothesis. We investigated the effect of elevat- ed circulating NEFA on insulin-mediated
hepatic glu- cose uptake (HGU) and whole-body glucose disposal (M) in eight healthy male
subjects. Methods. Studies were performed using positron emission tomography (PET) ... Cited by 12 - Related articles - BL Direct - All 5 versions
SA El-Batran, OME Abdel-Salam, SM Nofal, AR … - Pharmacological …, 2006 - Elsevier After the treatment, a significant reduction was observed in fasting blood glucose levels in all
groups. Rosiglitazone or metformin were found to exhibit a hypolipidaemic effect in diabetic rats
when administered alone or in combination. In comparison, nateglinide, when used ... Cited by 10 - Related articles - All 5 versions
- ►diabetesjournals.org MO Goodarzi, KD Taylor, X Guo, MJ Quiñones, J Cui, X … - Diabetes, 2005 - Am Diabetes Assoc The rising prevalence of the insulin resistance syndrome in our society necessitates a better
understanding of the genetic determinants of all aspects of insulin action and metabolism. We
evaluated the heritability of insulin sensitivity and the metabolic clearance rate of insulin ( ... Cited by 7 - Related articles - All 5 versions
